Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00042068 · ClinicalTrials.gov registry record · Phase 3
A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis
A Phase 3 study of Arthritis, Rheumatoid, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
- 20
- Study locations
NCT00042068: Completed Phase 3 study of Arthritis, Rheumatoid, sponsored by Boehringer Ingelheim.
NCT00042068 is a Phase 3 study of Arthritis, Rheumatoid that has completed, run by Boehringer Ingelheim. The registered enrollment target is 1,000 participants, above the 604-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target (66% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00042068, a Phase 3 study of Arthritis, Rheumatoid, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
A 12-week trial consisting of 5 visits (6 if follow up is needed) to find out how effective and safe three different doses of meloxicam are compared with placebo in Rheumatoid Arthritis. Patient will take one dose of study medication daily.
Conditions Studied
Interventions
- DRUG Meloxicam
Study Locations (20)
California
- Boehringer Ingelheim Investigational Site - Los Angeles
- Boehringer Ingelheim Investigational Site - Pasadena
- Suite 100 - Rancho Cucamonga
- Boehringer Ingelheim Investigational Site - Rancho Mirage
- Suite 208 - San Diego
- Suite 202 - San Diego
- Suite 301 - San Leandro
- Suite A - Santa Maria
- Westlake Medical Research - Westlake Village
Arizona
- #106 - Glendale
- Suite 601 - Phoenix
- Suite 201 - Phoenix
Alabama
- Suites 570 (research) & 600 (PI) - Huntsville
- Suite 200 - Montgomery
Florida
- Boehringer Ingelheim Investigational Site - Delray Beach
- Boehringer Ingelheim Investigational Site - Gainsville
Alaska
- Suite 140 - Anchorage
Colorado
- Suite 200 - Colorado Springs
Connecticut
- Suites 205 & 206 - Danbury
District of Columbia
- Suite 300 - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2002-06 |
| Est. Completion | 2003-07 |
| Phase | Phase 3 |
What the finished NCT00042068 record still lists
NCT00042068 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 604-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target (66% higher).
The record links to 1 condition, with Arthritis, Rheumatoid appearing as the primary indexed condition, and to 1 intervention - of which Meloxicam is the first listed.
NCT00042068 names 20 study sites across 8 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT00042068 about?
NCT00042068 is a clinical study titled "A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis". A 12-week trial consisting of 5 visits (6 if follow up is needed) to find out how effective and safe three different doses of meloxicam are compared with placebo in Rheumatoid Arthritis. Patient will take one dose of study medication daily.
What is the current status of trial NCT00042068?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2002-06. Estimated completion is 2003-07.
What conditions does trial NCT00042068 study?
This clinical trial studies the following conditions: Arthritis, Rheumatoid.
What interventions are being tested in trial NCT00042068?
The interventions under investigation include: Meloxicam (DRUG).
Who is sponsoring clinical trial NCT00042068?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00042068 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis, Rheumatoid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00042068's enrollment target sits among peer trials
1,000 4th of 27 higher than 24 of 27 other Arthritis, Rheumatoid trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Arthritis, Rheumatoid trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications
COMPLETED · Phase 3
-
Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
COMPLETED · Phase 3
-
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
COMPLETED · Phase 3
-
Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis
COMPLETED · Phase 3
-
Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis
COMPLETED · Phase 3
-
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia